Clinical features and treatment of maturity onset diabetes of the young (MODY)

Diabetes, Metabolic Syndrome and Obesity

Volumn 5, Issue , 2012, Pages 101-108

  Gardner, Daphne S L ^a   Shyong Tai, E ^b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

GCK; HNF1A; HNF1B; HNF4A; Type 1 diabetes; Type 2 diabetes

Indexed keywords

C REACTIVE PROTEIN; GLICLAZIDE; GLUCOSE; HEPATOCYTE NUCLEAR FACTOR 1; HEPATOCYTE NUCLEAR FACTOR 1 HOMEOBOX B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; METFORMIN; NEUROGENIC DIFFERENTIATION FACTOR; SULFONYLUREA; TRANSCRIPTION FACTOR PAX4; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ACANTHOSIS NIGRICANS; AGE DISTRIBUTION; ANTIDIABETIC ACTIVITY; BIRTH WEIGHT; CLINICAL FEATURE; DIABETOGENESIS; DISEASE CLASSIFICATION; GCK GENE; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; GLYCEMIC CONTROL; HEARING IMPAIRMENT; HETEROZYGOSITY; HNF4A GENE; HNFIA GENE; HNFIB GENE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; KETOACIDOSIS; LOW DRUG DOSE; MACROSOMIA; MONOGENIC DISORDER; NEURODI GENE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OPTIC NERVE ATROPHY; PANCREAS ISLET CELL HYPERPLASIA; PAX4 GENE; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TCF2 GENE; TREATMENT INDICATION; WOLFRAM SYNDROME;

EID: 84868292211     PISSN: 11787007     EISSN: None     Source Type: Journal    
DOI: 10.2147/dmso.s23353     Document Type: Review

References (84)

1. Tattersall RB. Mild familial diabetes with dominant inheritance. Q J Med. 1974;43(170):339-357.
2. Tattersall RB, Fajans SS. A difference between the inheritance of classical juvenile-onset and maturity-onset type diabetes of young people. Diabetes. 1975;24(1):44-53.
3. Yamagata K, Furuta H, Oda N, et al. Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1). Nature. 1996;384(6608):458-460.
4. Yamagata K, Oda N, Kaisaki PJ, et al. Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature. 1996;384(6608):455-458.
5. Vionnet N, Stoffel M, Takeda J, et al. Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus. Nature. 1992;356(6371):721-722.
6. Horikawa Y, Iwasaki N, Hara M, et al. Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. Nat Genet. 1997;17(4):384-385.
7. Stoffers DA, Ferrer J, Clarke WL, Habener JF. Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. Nat Genet. 1997;17(2):138-139.
8. Shepherd M, Ellis I, Ahmad AM, et al. Predictive genetic testing in maturity-onset diabetes of the young (MODY). Diabet Med. 2001;18(5):417-421.
9. Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia. 2010;53(12):2504-2508.
10. Estalella I, Rica I, Perez de Nanclares G, et al. Mutations in GCK and HNF-1alpha explain the majority of cases with clinical diagnosis of MODY in Spain. Clin Endocrinol (Oxf). 2007;67(4):538-546.
11. Schober E, Rami B, Grabert M, et al. Phenotypical aspects of maturityonset diabetes of the young (MODY diabetes) in comparison with type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicentre database. Diabet Med. 2009;26(5):466-473.
12. Porter JR, Rangasami JJ, Ellard S, et al. Asian MODY: are we missing an important diagnosis? Diabet Med. 2006;23(11):1257-1260.
13. McDonald TJ, Colclough K, Brown R, et al. Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes. Diabet Med. 2011;28(9):1028-1033.
14. Frayling TM, Bulamn MP, Ellard S, et al. Mutations in the hepatocyte nuclear factor-1alpha gene are a common cause of maturity-onset diabetes of the young in the UK. Diabetes. 1997;46(4):720-725.
15. Kaisaki PJ, Menzel S, Lindner T, et al. Mutations in the hepatocyte nuclear factor-1alpha gene in MODY and early-onset NIDDM: evidence for a mutational hotspot in exon 4. Diabetes. 1997;46(3):528-535.
16. Lehto M, Wipemo C, Ivarsson SA, et al. High frequency of mutations in MODY and mitochondrial genes in Scandinavian patients with familial early-onset diabetes. Diabetologia. 1999;42(9):1131-1137.
17. Gragnoli C, Cockburn BN, Chiaramonte F, et al. Early-onset type II diabetes mellitus in Italian families due to mutations in the genes encoding hepatic nuclear factor 1 alpha and glucokinase. Diabetologia. 2001;44(10):1326-1329.
18. Costa A, Bescos M, Velho G, et al. Genetic and clinical characterization of maturity-onset diabetes of the young in Spanish families. Eur J Endocrinol. 2000;142(4):380-386.
19. McKinney JL, Cao H, Robinson JF, et al. Spectrum of HNF1A and GCK mutations in Canadian families with maturity-onset diabetes of the young (MODY). Clin Invest Med. 2004;27(3):135-141.
20. Glucksmann MA, Lehto M, Tayber O, et al. Novel mutations and a mutational hotspot in the MODY3 gene. Diabetes. 1997;46(6): 1081-1086.
21. Iwasaki N, Oda N, Ogata M, et al. Mutations in the hepatocyte nuclear factor-1alpha/MODY3 gene in Japanese subjects with early- and lateonset NIDDM. Diabetes. 1997;46(9):1504-1508.
22. Xu JY, Dan QH, Chan V, et al. Genetic and clinical characteristics of maturity-onset diabetes of the young in Chinese patients. Eur J Hum Genet. 2005;13(4):422-427.
23. Pontoglio M, Sreenan S, Roe M, et al. Defective insulin secretion in hepatocyte nuclear factor 1alpha-deficient mice. J Clin Invest. 1998;101(10):2215-2222.
24. Wang H, Maechler P, Hagenfeldt KA, Wollheim CB. Dominantnegative suppression of HNF-1alpha function results in defective insulin gene transcription and impaired metabolism-secretion coupling in a pancreatic beta-cell line. EMBO J. 1998;17(22):6701-6713.
25. Wollheim CB. Beta-cell mitochondria in the regulation of insulin secretion: a new culprit in type II diabetes. Diabetologia. 2000;43(3): 265-277.
26. Harries LW, Ellard S, Stride A, Morgan NG, Hattersley AT. Isomers of the TCF1 gene encoding hepatocyte nuclear factor-1 alpha show differential expression in the pancreas and define the relationship between mutation position and clinical phenotype in monogenic diabetes. Hum Mol Genet. 2006;15(14):2216-2224.
27. Stride A, Ellard S, Clark P, et al. Beta-cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor1alpha mutation carriers. Diabetes Care. 2005;28(7):1751-1756.
28. Stride A, Vaxillaire M, Tuomi T, et al. The genetic abnormality in the beta cell determines the response to an oral glucose load. Diabetologia. 2002;45(3):427-435.
29. Pontoglio M, Prie D, Cheret C, et al. HNF1alpha controls renal glucose reabsorption in mouse and man. EMBO Rep. 2000;1(4):359-365.
30. Isomaa B, Henricsson M, Lehto M, et al. Chronic diabetic complications in patients with MODY3 diabetes. Diabetologia. 1998;41(4): 467-473.
31. Steele AM, Shields BM, Shepherd M, Ellard S, Hattersley AT, Pearson ER. Increased all-cause and cardiovascular mortality in monogenic diabetes as a result of mutations in the HNF1A gene. Diabet Med. 2010;27(2):157-161.
32. Pearson ER. HDL-cholesterol: differentiating between HNF1A MODY and type 2 diabetes (abstract). 2003;20(S22):S21-S33.
33. Heiervang E, Folling I, Sovik O, et al. Maturity-onset diabetes of the young. Studies in a Norwegian family. Acta Paediatr Scand. 1989;78(1): 74-80.
34. Sovik O, Njolstad P, Folling I, Sagen J, Cockburn BN, Bell GI. Hyper excitability to sulphonylurea in MODY3. Diabetologia. 1998; 41(5):607-608.
35. Pearson ER, Liddell WG, Shepherd M, Corrall RJ, Hattersley AT. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes. Diabet Med. 2000;17(7):543-545.
36. Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet. 2003;362(9392):1275-1281.
37. Shepherd M, Pearson ER, Houghton J, Salt G, Ellard S, Hattersley AT. No deterioration in glycemic control in HNF-1alpha maturity-onset diabetes of the young following transfer from long-term insulin to sulphonylureas. Diabetes Care. 2003;26(11):3191-3192.
38. Shepherd M, Shields B, Ellard S, Rubio-Cabezas O, Hattersley AT. A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. Diabet Med. 2009;26(4):437-441.
39. Tuomi T, Honkanen EH, Isomaa B, Sarelin L, Groop LC. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3. Diabetes Care. 2006;29(2):189-194.
40. Matschinsky FM. Evolution of the glucokinase glucose sensor paradigm for pancreatic beta cells. Diabetologia. 1993;36(11): 1215-1217.
41. Byrne MM, Sturis J, Clement K, et al. Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. J Clin Invest. 1994;93(3):1120-1130.
42. Martin D, Bellanne-Chantelot C, Deschamps I, Froguel P, Robert JJ, Velho G. Long-term follow-up of oral glucose tolerance test-derived glucose tolerance and insulin secretion and insulin sensitivity indexes in subjects with glucokinase mutations (MODY2). Diabetes Care. 2008;31(7):1321-1323.
43. Velho G, Blanche H, Vaxillaire M, et al. Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families. Diabetologia. 1997;40(2):217-224.
44. Steele AM, Shields BM, Shepherd M, Ellard S, Colclough K, Hattersley AT. Microvascular complication risk in patients with 50 years of moderate hyperglycaemia: are target ranges for glycaemic control appropriate? Abstract A77. Diabet Med. 2011;28(S1):2.
45. Hattersley AT, Pearson ER. Minireview: pharmacogenetics and beyond: the interaction of therapeutic response, beta-cell physiology, and genetics in diabetes. Endocrinology. 2006;147(6):2657-2663.
46. Hattersley A, Bruining J, Shield J, Njolstad P, Donaghue KC. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes. 2009;10 Suppl 12:33-42.
47. Spyer G, Hattersley AT, Sykes JE, Sturley RH, MacLeod KM. Influence of maternal and fetal glucokinase mutations in gestational diabetes. Am J Obstet Gynecol. 2001;185(1):240-241.
48. Malecki MT, Yang Y, Antonellis A, Curtis S, Warram JH, Krolewski AS. Identification of new mutations in the hepatocyte nuclear factor 4alpha gene among families with early onset Type 2 diabetes mellitus. Diabet Med. 1999;16(3):193-200.
49. Pruhova S, Ek J, Lebl J, et al. Genetic epidemiology of MODY in the Czech republic: new mutations in the MODY genes HNF-4alpha, GCK and HNF-1alpha. Diabetologia. 2003;46(2):291-295.
50. Frayling TM, Evans JC, Bulman MP, et al. Beta-cell genes and diabetes: molecular and clinical characterization of mutations in transcription factors. Diabetes. 2001;50 Suppl 1:S94-S100.
51. Pearson ER, Pruhova S, Tack CJ, et al. Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4alpha mutations in a large European collection. Diabetologia. 2005;48(5):878-885.
52. Carette C, Dubois-Laforgue D, Saint-Martin C, et al. Familial youngonset forms of diabetes related to HNF4A and rare HNF1A molecular aetiologies. Diabet Med. 2010;27(12):1454-1458.
53. Ellard S, Bellanne-Chantelot C, Hattersley AT. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia. 2008;51(4):546-553.
54. Pearson ER, Boj SF, Steele AM, et al. Macrosomia and hyperinsulinaemic hypo glycaemia in patients with heterozygous mutations in the HNF4A gene. PLoS Med. 2007;4(4):e118.
55. Fajans SS, Brown MB. Administration of sulfonylureas can increase glucose-induced insulin secretion for decades in patients with maturityonset diabetes of the young. Diabetes Care. 1993;16(9):1254-1261.
56. Coffinier C, Thepot D, Babinet C, Yaniv M, Barra J. Essential role for the homeoprotein vHNF1/HNF1beta in visceral endoderm differentiation. Development. 1999;126(21):4785-4794.
57. Ulinski T, Lescure S, Beaufils S, et al. Renal phenotypes related to hepatocyte nuclear factor-1beta (TCF2) mutations in a pediatric cohort. J Am Soc Nephrol. 2006;17(2):497-503.
58. Iwasaki N, Ogata M, Tomonaga O, et al. Liver and kidney function in Japanese patients with maturity-onset diabetes of the young. Diabetes Care. 1998;21(12):2144-2148.
59. Montoli A, Colussi G, Massa O, et al. Renal cysts and diabetes syndrome linked to mutations of the hepatocyte nuclear factor-1 beta gene: description of a new family with associated liver involvement. Am J Kidney Dis. 2002;40(2):397-402.
60. Bellanne-Chantelot C, Chauveau D, Gautier JF, et al. Clinical spectrum associated with hepatocyte nuclear factor-1beta mutations. Ann Intern Med. 6 2004;140(7):510-517.
61. Edghill EL, Bingham C, Slingerland AS, et al. Hepatocyte nuclear factor-1 beta mutations cause neonatal diabetes and intrauterine growth retardation: support for a critical role of HNF-1beta in human pancreatic development. Diabet Med. 2006;23(12):1301-1306.
62. Faguer S, Decramer S, Chassaing N, et al. Diagnosis, management, and prognosis of HNF1B nephropathy in adulthood. Kidney Int. 2011;80(7):768-776.
63. Goto Y, Nonaka I, Horai S. A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature. 13, 1990;348(6302):651-653.
64. Kobayashi T, Nakanishi K, Nakase H, et al. In situ characterization of islets in diabetes with a mitochondrial DNA mutation at nucleotide position 3243. Diabetes. 1997;46(10):1567-1571.
65. Walker M, Taylor RW, Stewart MW, et al. Insulin and proinsulin secretion in subjects with abnormal glucose tolerance and a mitochondrial tRNA(Leu(UUR)) mutation. Diabetes Care. 1995;18(11):1507-1509.
66. Maassen JA, 'T Hart LM, Van Essen E, et al. Mitochondrial diabetes: molecular mechanisms and clinical presentation. Diabetes. 2004; 53 Suppl 1:S103-S109.
67. Kristinsson SY, Thorolfsdottir ET, Talseth B, et al. MODY in Iceland is associated with mutations in HNF-1alpha and a novel mutation in NeuroD1. Diabetologia. 2001;44(11):2098-2103.
68. Liu L, Furuta H, Minami A, et al. A novel mutation, Ser159Pro in the NeuroD1/BETA2 gene contributes to the development of diabetes in a Chinese potential MODY family. Mol Cell Biochem. 2007;303(1-2):115-120.
69. Malecki MT, Jhala US, Antonellis A, et al. Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus. Nat Genet. 1999;23(3):323-328.
70. Plengvidhya N, Kooptiwut S, Songtawee N, et al. PAX4 mutations in Thais with maturity onset diabetes of the young. J Clin Endocrinol Metab. 2007;92(7):2821-2826.
71. Raeder H, Johansson S, Holm PI, et al. Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction. Nat Genet. 2006;38(1):54-62.
72. Jo W, Endo M, Ishizu K, Nakamura A, Tajima T. A novel PAX4 mutation in a Japanese patient with maturity-onset diabetes of the young. Tohoku J Exp Med. 2011;223(2):113-118.
73. Cho YS, Chen CH, Hu C, et al. Meta-analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in east Asians. Nat Genet. 2012;44(1):67-72.
74. Kooner JS, Saleheen D, Sim X, et al. Genome-wide association study in individuals of South Asian ancestry identifies six new type 2 diabetes susceptibility loci. Nat Genet. 2011;43(10):984-989.
75. Saxena R, Elbers CC, Guo Y, et al. Large-scale gene-centric metaanalysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet. 2012;90(3):410-425.
76. Thanabalasingham G, Pal A, Farmer AJ, Ellard S, McCarthy MI, Owen KR. Extending criteria for genetic testing increases diagnosis of maturity-onset diabetes of the young. Diabetologia. 2010;53:S63.
77. Reiner AP, Barber MJ, Guan Y, et al. Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein. Am J Hum Genet. 2008;82(5):1193-1201.
78. Toniatti C, Demartis A, Monaci P, Nicosia A, Ciliberto G. Synergistic trans-activation of the human C-reactive protein promoter by transcription factor HNF-1 binding at two distinct sites. EMBO J. 1990;9(13):4467-4475.
79. Owen KR, Thanabalasingham G, James TJ, et al. Assessment of highsensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations. Diabetes Care. 2010;33(9):1919-1924.
80. McDonald TJ, Shields BM, Lawry J, et al. High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes. Diabetes Care. 2011;34(8):1860-1862.
81. Thanabalasingham G, Shah N, Vaxillaire M, et al. A large multicentre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes. Diabetologia. 2011;54(11):2801-2810.
82. Bellanne-Chantelot C, Levy DJ, Carette C, et al. Clinical characteristics and diagnostic criteria of maturity-onset diabetes of the young (MODY) due to molecular anomalies of the HNF1A gene. J Clin Endocrinol Metab. 2011;96(8):E1346-E1351.
83. Schwitzgebel VM, Mamin A, Brun T, et al. Agenesis of human pancreas due to decreased half-life of insulin promoter factor 1. J Clin Endocrinol Metab. 2003;88(9):4398-4406.
84. Thomas IH, Saini NK, Adhikari A, et al. Neonatal diabetes mellitus with pancreatic agenesis in an infant with homozygous IPF-1 Pro63fsX60 mutation. Pediatr Diabetes. 2009;10(7):492-496.